Chin up, Kythera gets ATX-101 back from Bayer
This article was originally published in Scrip
Kythera Biopharmaceuticals spun Bayer's decision to offload the double chin drug ATX-101 as a positive change for the Calabasas, California-based company, which paid $33m in stock to reacquire global rights to the injectable aesthetic therapy.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.